Progression-Free Survival (PFS)

Researchers are studying the effects of different methods of lymph node removal on the prognosis of small ground glass nodules in the lungs. The nodules involved are less than 3 cm in size and have more than 50% solid components. This study is conducted across multiple centers to better understand the best approach for these cases and is sponsored by Shanghai Zhongshan Hospital. Participants with ground glass nodules that meet the size and composition criteria will be randomly assigned to one of two groups: selective lymphadenectomy or systematic lymph node dissection. Both are surgical procedures aimed at removing lymph nodes, but they differ in how extensive the removal is. The study will monitor participants for five years to assess overall survival. During the study, participants will be evaluated through lung CT scans and other clinical assessments to monitor their progress and response to the lymph node removal methods. Researchers will track overall survival over a five-year period to determine which surgical approach may offer better outcomes. Participants will be followed regularly to ensure adherence to the study and track any changes in their condition throughout the study duration, which started in 2020 and is expected to complete by the end of 2028.

Researchers are studying whether a new method of defining the radiation target areas can improve progression-free survival and reduce radiation complications in patients with high-grade glioma. This trial compares this new target delineation approach with the standard European Organisation for Research and Treatment of Cancer (EORTC) method. The goal is to see if the new method leads to better outcomes for patients after surgery. Participants will be randomly assigned to one of two groups. The trial group receives radiotherapy using the new target delineation scheme based on CT-MRI fusion images, with careful dose limits to protect sensitive brain areas. The control group receives radiotherapy following the EORTC target delineation method. Both groups receive temozolomide chemotherapy concurrently during radiotherapy at 75 mg/m² daily, followed by six cycles of adjusted temozolomide dosing after radiotherapy. During the study, participants will be monitored for progression-free survival up to three years after randomization. Researchers will also evaluate overall survival, quality of life using the EORTC QLQ-C30 questionnaire, and the incidence of radiation-related complications. Follow-up visits and assessments will continue through study completion to track these outcomes and ensure patient safety.

Researchers are conducting a phase II clinical study at two centers to assess the safety and effectiveness of ablation therapy for treating lung cancer that appears as ground-glass nodules on lung CT scans. This study focuses on patients with such nodules that have not decreased after 3 months and meet specific size and progression criteria. The study is sponsored by Shanghai Zhongshan Hospital and aims to provide important data on this treatment approach for lung cancer progression. Participants will receive ablation therapy targeting ground-glass nodules in the lungs. This single-arm study involves no comparison group and no blinding. Ablation therapy is being evaluated as an alternative for patients who cannot tolerate surgery or have multiple nodules that cannot be fully removed by operation. The treatment focuses on nodules larger than 8 mm but smaller than 3 cm, especially those showing progression. During the study, participants will be monitored for progression-free survival over one year as the primary outcome. Secondary outcomes include overall survival evaluated at one, three, and five years. Participants will undergo lung CT scans and other assessments as needed to track treatment effects and safety. The total participation period extends up to five years for long-term follow-up of survival outcomes.

Researchers are evaluating the combination of candenizumab, lenvatinib, and the SOX regimen for treating patients with HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma that cannot be removed by surgery. The study focuses on patients who have not previously received systemic treatment for their advanced or metastatic disease, aiming to measure the objective response rate and observe survival outcomes and safety. The sponsor is Fujian Medical University. The study includes a phase 1 ramp-up test to adjust the dose of lenvatinib, followed by phase 2 treatment with six cycles of the combined drugs given every three weeks. Patients who do not experience disease progression enter phase 3, which involves maintenance therapy with candenizumab, lenvatinib, and tigio also every three weeks. This multi-stage treatment plan is designed to evaluate the combination therapy's effects and safety over time. Participants will be monitored regularly with assessments of tumor response, survival times, and quality of life changes. Safety evaluations include tracking adverse events, dose adjustments, and treatment pauses. The study requires participants to have measurable lesions, normal organ function, and an estimated survival time longer than three months. The total study period extends through treatment and follow-up, allowing researchers to gather comprehensive data on treatment response and tolerability.

Researchers are conducting an observational study on patients with gynecologic cancers who have been treated with advanced radiotherapy techniques such as Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), and Stereotactic Body Radiotherapy (SBRT). The study aims to analyze toxicity levels and clinical outcomes including tumor control and survival rates. The study includes patients treated at the IRCCS San Raffaele Scientific Institute between January 2005 and January 2024. The study involves reviewing clinical and dosimetric data from these patients to assess acute and late treatment-related toxicities and to evaluate outcomes like local, regional, and distant control of the cancer, disease-free survival, cancer-specific survival, and overall survival. Researchers will also explore factors that may predict toxicity, disease progression, and survival, including radiomic characteristics from imaging. Participants' medical records and treatment details will be analyzed without any additional interventions. The primary measurements include survival without relapse or metastases over up to 120 months after radiotherapy completion, as well as acute toxicity within three months and late toxicity beyond three months after treatment. This long-term follow-up is intended to provide insights into the safety and effectiveness of advanced radiotherapy for gynecologic cancers.

Researchers are evaluating different antimicrobial therapies for infections caused by difficult-to-treat Pseudomonas aeruginosa, a type of bacteria resistant to many common antibiotics. This study focuses on comparing new beta-lactam/beta-lactamase inhibitor combinations, cefiderocol, and older treatments like aminoglycosides and colistin to understand their effectiveness in real-life settings for patients facing these challenging infections. The study is a prospective, multicenter cohort involving patients who require intravenous antibiotic treatment for their P. aeruginosa infections. Participating patients will receive one of the available antimicrobial options, and their bacterial samples will be analyzed centrally to assess susceptibility and resistance mechanisms. The study collects clinical data throughout treatment and monitors outcomes such as cure rates, resistance development, adverse events, and mortality. Participants will be followed until hospital discharge and up to 28 days after treatment completion. Researchers will track clinical cures, microbiological eradication, adverse events, emergence of resistance, and acquisition of other multidrug-resistant bacteria. Data collection includes electronic case reports and laboratory testing on bacterial isolates. The total participation duration varies according to hospital stay and follow-up schedules, with rigorous monitoring of safety and treatment outcomes.

Researchers are examining how exercise affects cancer-specific outcomes and other health measures in adult cancer survivors. This retrospective study uses observational data to mimic a clinical trial, aiming to understand the impact of exercise after cancer treatment. The study is sponsored by Memorial Sloan Kettering Cancer Center and focuses on patients who have completed primary cancer treatment and are under surveillance for recurrence or remission. Participants are divided into groups based on their exercise habits following treatment. One group follows usual care, while the other group reports engaging in exercise after completing active therapy for their primary cancer. The study uses data from exercise surveys completed as part of the Cancer Survivorship Program at Memorial Sloan Kettering, assessing exercise levels at baseline and historically to classify non-exercising and exercising patients. During the study, participants' exercise status is tracked through surveys, and clinical outcomes such as distant disease-free survival over five years are measured. Researchers will review medical records to confirm no recurrence or metastasis before baseline assessment. Data collection includes patient-reported exercise frequency and intensity as well as clinical monitoring carried out during routine cancer survivorship care. The study spans data collected between 2011 and 2023, with ongoing follow-up to evaluate long-term outcomes.

Psychological distress, involving emotional, social, spiritual, and physical challenges, can affect how well patients cope with lung cancer and its treatment. This research focuses on patients with advanced lung cancer receiving immunotherapy or targeted therapy, aiming to explore how psychological stress relates to treatment effectiveness and survival outcomes. Participants in this observational study are patients with advanced lung cancer undergoing immunotherapy or targeted molecular therapy. The study observes the association between their psychological distress and the results of these anti-tumor treatments, without introducing new treatments or interventions. During the study, researchers will track measures such as objective response rate, disease control rate, and progression-free survival over a 20-year period. Overall survival is also monitored as a secondary outcome. Participants will provide information through assessments related to psychological distress, which will help evaluate how stress impacts treatment outcomes and patient prognosis.

Researchers are evaluating 3-year disease-free survival in patients with early-stage non-small cell lung cancer (NSCLC) who have minimal residual disease (MRD) positive for EGFR-sensitive mutations after surgery. The study compares the outcomes of patients treated with adjuvant befortinib, an oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor, against those under routine observation. This prospective trial focuses on patients with high-risk factors following complete tumor removal in stages IA2 to IB NSCLC. Participants receive befortinib as an adjuvant therapy after surgery, or they are monitored under routine observation without additional treatment. The study includes patients who have undergone R0 resection with specific tumor sizes and confirmed EGFR mutations, along with at least two high-risk pathological features. Treatment details include oral befortinib administration during the adjuvant period, with follow-up to assess disease progression. During the study, participants undergo MRD screening and regular follow-up visits to monitor their health status and disease-free survival over three years. Researchers assess outcomes such as disease recurrence and survival rates, alongside safety and organ function tests. Participants must comply with scheduled evaluations and provide informed consent, with the study duration extending up to three years to evaluate long-term disease-free outcomes.

Researchers are evaluating the safety and effectiveness of combining bevacizumab with cisplatin compared to cisplatin alone for treating malignant serous effusion in patients with advanced adenocarcinoma. This is a phase II, three-center, randomized clinical study sponsored by Qingdao Central Hospital. The study focuses on overall response rates at 4 weeks to understand how well the treatments control serous effusion in this patient group. Participants will be randomly assigned to one of two treatment groups. One group receives an intracavity injection of bevacizumab at 7.5 mg/kg combined with cisplatin at 40 mg/m2, with a repeat dose on the 21st day if the serous effusion is not controlled. The other group receives cisplatin alone at 40 mg/m2 via intracavity injection. Both treatments are administered directly into the cavity where the effusion is present. During the study, participants will be monitored for treatment response at 4 weeks to assess the overall response rate of the serous effusion. Safety and efficacy are carefully observed throughout the treatment period. Patients must meet specific health and laboratory criteria to participate, and their progress will be tracked to ensure their well-being and to gather important data on the treatments' effects. The study is expected to run until May 2027.